Technology ID
TAB-3347
Optimized Variants of the Broadly Neutralizing HIV-1 gp41 Antibody, 10E8
E-Numbers
E-133-2015-0
Lead Inventor
Kwong, Peter (NIAID)
Co-Inventors
Georgiev, Ivelin (NIAID)
Kwon, Young Do (NIAID)
Ofek, Gilad (NIAID)
Zhang, Baoshan (NIAID)
McKee, Krisha (NIAID)
Mascola, John (NIAID)
Chuang, Gwo-Yu (NIAID)
O'Dell, Sijy (NIAID)
Bailer, Robert (NIAID)
Louder, Mark (NIAID)
Asokan, Mangaiarkarasi (NIAID)
Cooper, Jonathan (NIAID)
Carlton, Kevin (NIAID)
Bender, Michael (NIAID)
Connors, Mark (NIAID)
Pegu, Amarendra ("Amar") (NIAID)
Kueltzo, Lisa (NIAID)
Shapiro, Lawrence (Columbia University)
Gindin, Tatyana (The Trustees of Columbia University In The City of New York)
Schwartz, Richard (NIAID)
Lead IC
NIAID
ICs
NIAID
Scientists at the National Institute of Allergy and Infectious Diseases (NIAID) recently discovered a human neutralizing antibody, 10E8, that binds to the GP41 protein of HIV-1 and prevents infection by HIV-1. 10E8 potently neutralizes up to 98% of genetically diverse HIV-1 strains.
By engineering the 10E8 antibody, NIAID scientists have improved the properties of 10E8 that affect manufacturability, such as solubility, while preserving its neutralizing breadth and potency.
10E8 variants are useful for passive protection from infection, as therapeutics, and as a tool for vaccine development.
This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR Part 404.
By engineering the 10E8 antibody, NIAID scientists have improved the properties of 10E8 that affect manufacturability, such as solubility, while preserving its neutralizing breadth and potency.
10E8 variants are useful for passive protection from infection, as therapeutics, and as a tool for vaccine development.
This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR Part 404.
Commercial Applications
- Passive protection to prevent HIV infection
- Passive protection to prevent mother-to-infant HIV transmission
- Gene-based vectors for anti-gp41 antibody expression
- Therapeutics for elimination of HIV infected cells that are actively producing virus
Competitive Advantages
- Among the most potent and broadly neutralizing human antibodies isolated to date
- Broad reactivity and high affinity to most HIV-1 strains
- Improved manufacturability relative to the natural 10E8 antibody
Licensing Contact: